James R Butler1, Gregory R Martens1, Jose L Estrada1, Luz M Reyes1, Joseph M Ladowski1, Cesare Galli2,3, Andrea Perota2, Conor M Cunningham1, Matthew Tector1, A Joseph Tector4. 1. Department of Surgery, Indiana University School of Medicine, UH 4601 550 N. University Blvd, Indianpolis, IN, 46202, USA. 2. Avantea Laboratorio Di Tecnologie Della Riproduzione, Cermona, Italy. 3. Department of Veterinary Medical Sciences, University of Bologna, Bologna, Ozzano Emilia, Italy. 4. Department of Surgery, Indiana University School of Medicine, UH 4601 550 N. University Blvd, Indianpolis, IN, 46202, USA. jtector@uab.edu.
Abstract
UNLABELLED: The future of solid organ transplantation is challenged by an increasing shortage of available allografts. Xenotransplantation of genetically modified porcine organs offers an answer to this problem. Strategies of genetic modification have 'humanized' the porcine model towards clinical relevance. Most notably, these approaches have aimed at either antigen reduction or human transgene expression. The object of this study was to evaluate the relative effects of both antigen reduction and direct complement regulation on the human-anti-porcine complement dependent cytotoxicity response. Genetically modified animals were created through CRISPR/Cas9-directed mutation and human transgene delivery. Pigs doubly deficient in GGTA1 and CMAH genes were compared to pigs of the same background that expressed a human complement regulatory protein (hCRP). A third animal was made deficient in GGTA1, CMAH and B4GalNT2 gene expression. Cells from these animals were subjected to measures of human antibody binding and antibody-mediated complement-dependent cytotoxicity by flow cytometry. Human IgG and IgM antibody binding was unchanged between the double knockout and the transgenic hCRP double knockout pig. IgG and IgM binding was reduced by 49.1 and 43.2 % respectively by silencing the B4GalNT2 gene. Compared to the double knockout, human anti-porcine cytotoxicity was reduced by 8 % with the addition of a hCRP (p = .032); It was reduced by 21 % with silencing the B4GalNT2 gene (p = .012). CONCLUSIONS: Silencing the GGTA1, CMAH and B4GalNT2 genes in pigs achieved a significant antigen reduction. Changing the porcine carbohydrate profile effectively mediates human antibody-mediated complement dependent cytoxicity.
UNLABELLED: The future of solid organ transplantation is challenged by an increasing shortage of available allografts. Xenotransplantation of genetically modified porcine organs offers an answer to this problem. Strategies of genetic modification have 'humanized' the porcine model towards clinical relevance. Most notably, these approaches have aimed at either antigen reduction or human transgene expression. The object of this study was to evaluate the relative effects of both antigen reduction and direct complement regulation on the human-anti-porcine complement dependent cytotoxicity response. Genetically modified animals were created through CRISPR/Cas9-directed mutation and human transgene delivery. Pigs doubly deficient in GGTA1 and CMAH genes were compared to pigs of the same background that expressed a human complement regulatory protein (hCRP). A third animal was made deficient in GGTA1, CMAH and B4GalNT2 gene expression. Cells from these animals were subjected to measures of human antibody binding and antibody-mediated complement-dependent cytotoxicity by flow cytometry. Human IgG and IgM antibody binding was unchanged between the double knockout and the transgenic hCRP double knockout pig. IgG and IgM binding was reduced by 49.1 and 43.2 % respectively by silencing the B4GalNT2 gene. Compared to the double knockout, human anti-porcine cytotoxicity was reduced by 8 % with the addition of a hCRP (p = .032); It was reduced by 21 % with silencing the B4GalNT2 gene (p = .012). CONCLUSIONS: Silencing the GGTA1, CMAH and B4GalNT2 genes in pigs achieved a significant antigen reduction. Changing the porcine carbohydrate profile effectively mediates human antibody-mediated complement dependent cytoxicity.
Authors: Jose L Estrada; Greg Martens; Ping Li; Andrew Adams; Kenneth A Newell; Mandy L Ford; James R Butler; Richard Sidner; Matt Tector; Joseph Tector Journal: Xenotransplantation Date: 2015-03-01 Impact factor: 3.907
Authors: C Burlak; L L Paris; A J Lutz; R A Sidner; J Estrada; P Li; M Tector; A J Tector Journal: Am J Transplant Date: 2014-06-06 Impact factor: 8.086
Authors: Christopher G A McGregor; Davide Ricci; Naoto Miyagi; Paul G Stalboerger; Zeji Du; Elise A Oehler; Henry D Tazelaar; Guerard W Byrne Journal: Transplantation Date: 2012-04-15 Impact factor: 4.939
Authors: Guerard W Byrne; Paul G Stalboerger; Zeji Du; Tessa R Davis; Christopher G A McGregor Journal: Transplantation Date: 2011-02-15 Impact factor: 4.939
Authors: Liangxue Lai; Donna Kolber-Simonds; Kwang-Wook Park; Hee-Tae Cheong; Julia L Greenstein; Gi-Sun Im; Melissa Samuel; Aaron Bonk; August Rieke; Billy N Day; Clifton N Murphy; David B Carter; Robert J Hawley; Randall S Prather Journal: Science Date: 2002-01-03 Impact factor: 47.728
Authors: Carol J Phelps; Chihiro Koike; Todd D Vaught; Jeremy Boone; Kevin D Wells; Shu-Hung Chen; Suyapa Ball; Susan M Specht; Irina A Polejaeva; Jeff A Monahan; Pete M Jobst; Sugandha B Sharma; Ashley E Lamborn; Amy S Garst; Marilyn Moore; Anthony J Demetris; William A Rudert; Rita Bottino; Suzanne Bertera; Massimo Trucco; Thomas E Starzl; Yifan Dai; David L Ayares Journal: Science Date: 2002-12-19 Impact factor: 47.728
Authors: Nienke de Graeff; Karin R Jongsma; Josephine Johnston; Sarah Hartley; Annelien L Bredenoord Journal: Philos Trans R Soc Lond B Biol Sci Date: 2019-05-13 Impact factor: 6.237
Authors: Joseph M Ladowski; Gregory R Martens; Luz M Reyes; Zheng-Yu Wang; Devin E Eckhoff; Vera Hauptfeld-Dolejsek; Matt Tector; A Joseph Tector Journal: J Immunol Date: 2018-03-14 Impact factor: 5.422
Authors: Hironosuke Watanabe; Yuichi Ariyoshi; Thomas Pomposelli; Kazuhiro Takeuchi; Dilrukshi K Ekanayake-Alper; Lennan K Boyd; Scott J Arn; Hisashi Sahara; Akira Shimizu; David Ayares; Marc I Lorber; Megan Sykes; David H Sachs; Kazuhiko Yamada Journal: Xenotransplantation Date: 2019-09-23 Impact factor: 3.907